Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia

This study has been terminated.
(Sponsor wanted study rewritten)
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Roswell Park Cancer Institute Identifier:
First received: March 7, 2012
Last updated: April 4, 2016
Last verified: April 2016
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: December 2014
  Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)